Larynx News and Research

RSS

Cancer vaccines receive orphan drug designation for advanced head and neck cancer

Two experimental vaccines from the University of Maryland, Baltimore (UMB) recently received a federal orphan drug designation for advanced head and neck cancer, according to a company official.

9 Apr 2009

3-drug chemotherapy combo increases organ preservation in patients with larynx cancer

Patients with larynx cancer who received a three-drug combination of docetaxel, cisplatin and 5-fluorouracil (TPF) during induction chemotherapy were more likely to retain larynx function than were patients treated with cisplatin and 5-fluoruracil (PF) alone, according to data from a randomized controlled trial in the March 24 online issue of the Journal of the National Cancer Institute.

24 Mar 2009

More cancer patients cured according to new data on cancer survival in Europe

New data and analyses from a long-running study of cancer survival in Europe have shown that the number of people actually cured of cancer - rather than just surviving for at least five years after diagnosis - is rising steadily.

23 Mar 2009

Discovery of genetic markers for aggressive head and neck cancer

Scientists at Albert Einstein College of Medicine of Yeshiva University have identified genetic markers that signal poor outcomes for patients with head and neck cancer.

20 Mar 2009

Low to moderate alcohol consumption among women associated with increased cancer risk

Low to moderate alcohol consumption among women is associated with a statistically significant increase in cancer risk and may account for nearly 13 percent of the cancers of the breast, liver, rectum, and upper aero-digestive tract combined, according to a report in the February 24 online issue of the Journal of the National Cancer Institute.

24 Feb 2009

FDA grants priority review of Cinryze C1 inhibitor as treatment for acute attacks of hereditary angioedema

ViroPharma Incorporated has announced that the U.S. Food and Drug Administration (FDA) has granted priority review for Cinryze C1 Inhibitor (human) as a treatment for acute attacks of Hereditary Angioedema (HAE).

5 Feb 2009

Sequential and alternating chemotherapy and radiation equally effective in larynx cancer therapy

Larynx cancer patients treated with alternating cycles of chemotherapy and radiation have similar outcomes to patients treated with chemotherapy followed by radiation, according to data from a randomized controlled trial in the January 27 online issue of the Journal of the National Cancer Institute.

29 Jan 2009

Time to celebrate? Be warned! One tipple a day increases the risk of cancer

In the run up to the New Year's Eve festivities a scientist in Britain has chosen an opportune moment to warn revellers that drinking alcohol, even in relatively small amounts, can increase a tipplers risk of developing cancer.

29 Dec 2008

Broccoli compound, indole-3-carbinol targets key enzyme in late-stage cancer

An anti-cancer compound found in broccoli and cabbage works by lowering the activity of an enzyme associated with rapidly advancing breast cancer, according to a University of California, Berkeley, study appearing this week in the online early edition of the journal Proceedings of the National Academy of Sciences.

3 Dec 2008

ViroPharma Inc. submits sBLA for Cinryze to treat acute attacks of hereditary angioedema

ViroPharma Inc. has announced that the company submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Cinryze C1 Inhibitor (human) as a treatment for acute attacks of hereditary angioedema (HAE).

1 Dec 2008

Declines in cancer incidence and death rates across U.S.

A new report from the nation's leading cancer organizations shows that, for the first time since the report was first issued in 1998, both incidence and death rates for all cancers combined are decreasing for both men and women, driven largely by declines in some of the most common types of cancer.

25 Nov 2008

New voice care center

UT Southwestern Medical Center has gathered a team of specially trained physicians and therapists to launch a new center for voice care dedicated to disorders of the voice and larynx.

24 Nov 2008

FDA accepts filing and grants priority review for DX-88 for hereditary angioedema

Dyax Corp. has announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's Biologics License Application (BLA) for DX-88 (ecallantide) for the treatment of acute attacks of hereditary angioedema (HAE) and has designated the application for Priority Review.

21 Nov 2008

Survival of head and neck cancer patients is greatly affected by coexisting ailments

Current estimates for head and neck cancer survival are largely inaccurate because they widely disregard many of the most common diseases such patients have in addition to their primary cancer, says Jay Piccirillo, M.D., a head and neck specialist at Washington University School of Medicine in St. Louis, the Siteman Cancer Center and Barnes-Jewish Hospital.

19 Nov 2008

FDA licenses for marketing Cinryze for hereditary angioedema

The U.S. Food and Drug Administration today licensed for marketing the first product in the United States intended to protect people with hereditary angioedema (HAE), a rare and potentially life-threatening genetic disease. HAE affects about 6,000 to 10,000 individuals in the United States.

12 Oct 2008

In just 5 years tobacco caused 2.4 million cases of cancer in the U.S.

The latest report from the Centers for Disease Control and Prevention (CDC) in the U.S. reveals some shocking figures.

8 Sep 2008

Public backs tougher tobacco control to protect the young

More than 8,000 people have written to the Department of Health calling for tougher tobacco control to protect young people and put tobacco out of sight and out of mind.

7 Sep 2008

Smoking ban triggered the biggest fall in smoking ever seen in England

Smokefree law in England has helped more smokers to quit than ever before and will help prevent an estimated 40,000 deaths over the next 10 years - according to new research being presented in Birmingham tomorrow (Tuesday).

30 Jun 2008

Cetuximab and chemotherapy combination proves safe, effective for head and neck cancer patients

Patients treated for locally advanced head and neck cancer may respond better to treatment with the addition of cetuximab to chemotherapy, according to a University of Pittsburgh Cancer Institute (UPCI) phase II study. The results will be presented at the 44th annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago as an oral presentation.

2 Jun 2008

Why do some heavy drinkers develop mouth and throat cancers while others do not?

A study by researchers in Europe has revealed why some heavy drinkers develop mouth and throat cancers while others do not and also why some people get drunk quickly.

26 May 2008